Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa

被引:25
作者
Schwarz, J
Scheidtmann, K
Trenkwalder, C
机构
[1] UNIV MUNICH, KLINIKUM GROSSHADERN, DEPT NEUROL, MUNICH, GERMANY
[2] MAX PLANCK INST PSYCHIAT, INST CLIN, D-80804 MUNICH, GERMANY
关键词
Parkinson's disease; motor fluctuations; dopamine agonist; pergolide; levodopa;
D O I
10.1159/000117449
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The combination of levodopa and a dopamine agonist in the treatment of patients with Parkinson's disease often reduces the severity of motor fluctuations. In patients with very severe motor fluctuations, monotherapy with continuous subcutaneous infusions of the dopamine agonist apomorphine may result in a marked reduction of hyperkinesia and on-off phenomena. We report 3 patients with Parkinson's disease and motor fluctuations who received high doses of pergolide without levodopa resulting in a reduction of motor fluctuations. All patients received doses of pergolide exceeding the maximum recommended dose. One patient also required additional therapy with amantadine. These data show that in some patients oral treatment with high doses of a dopamine agonist may improve the severity of motor fluctuations and achieve a good control of parkinsonian signs without concomitant levodopa treatment.
引用
收藏
页码:236 / 238
页数:3
相关论文
共 12 条
[1]   High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias [J].
Facca, A ;
SanchezRamos, J .
MOVEMENT DISORDERS, 1996, 11 (03) :327-329
[2]   APOMORPHINE INFUSIONAL THERAPY IN PARKINSONS-DISEASE - CLINICAL UTILITY AND LACK OF TOLERANCE [J].
GANCHER, ST ;
NUTT, JG ;
WOODWARD, WR .
MOVEMENT DISORDERS, 1995, 10 (01) :37-43
[3]   THE SYDNEY MULTICENTER STUDY OF PARKINSONS-DISEASE - A RANDOMIZED, PROSPECTIVE 5-YEAR STUDY COMPARING LOW-DOSE BROMOCRIPTINE WITH LOW-DOSE LEVODOPA-CARBIDOPA [J].
HELY, MA ;
MORRIS, JGL ;
REID, WGJ ;
OSULLIVAN, DJ ;
WILLIAMSON, PM ;
RAIL, D ;
BROE, GA ;
MARGRIE, S .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1994, 57 (08) :903-910
[4]   SUBCUTANEOUS APOMORPHINE IN PARKINSONS-DISEASE - RESPONSE TO CHRONIC ADMINISTRATION FOR UP TO 5 YEARS [J].
HUGHES, AJ ;
BISHOP, S ;
KLEEDORFER, B ;
TURJANSKI, N ;
FERNANDEZ, W ;
LEES, AJ ;
STERN, GM .
MOVEMENT DISORDERS, 1993, 8 (02) :165-170
[5]   EFFECTS OF THE 1-AMINO-ADAMANTANES AT THE MK-801-BINDING SITE OF THE NMDA-RECEPTOR-GATED ION CHANNEL - A HUMAN POSTMORTEM BRAIN STUDY [J].
KORNHUBER, J ;
BORMANN, J ;
HUBERS, M ;
RUSCHE, K ;
RIEDERER, P .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1991, 206 (04) :297-300
[6]   PERGOLIDE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN PARKINSONS-DISEASE [J].
LANGTRY, HD ;
CLISSOLD, SP .
DRUGS, 1990, 39 (03) :491-506
[7]  
Loschmann P A, 1992, J Neural Transm Suppl, V38, P55
[8]   A RANDOMIZED CONTROLLED-STUDY COMPARING BROMOCRIPTINE TO WHICH LEVODOPA WAS LATER ADDED, WITH LEVODOPA ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH PARKINSONS-DISEASE - A 5-YEAR FOLLOW-UP [J].
MONTASTRUC, JL ;
RASCOL, O ;
SENARD, JM ;
RASCOL, A .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1994, 57 (09) :1034-1038
[9]   NATIONWIDE COLLABORATIVE STUDY ON THE LONG-TERM EFFECTS OF BROMOCRIPTINE IN THE TREATMENT OF PARKINSONIAN-PATIENTS - FINAL REPORT [J].
NAKANISHI, T ;
IWATA, M ;
GOTO, I ;
KANAZAWA, I ;
KOWA, H ;
MANNEN, T ;
MIZUNO, Y ;
NISHITANI, H ;
OGAWA, N ;
TAKAHASHI, A ;
TASHIRO, K ;
TOHGI, H ;
YANAGISAWA, N .
EUROPEAN NEUROLOGY, 1992, 32 :9-22
[10]   LONG-DURATION RESPONSE TO LEVODOPA [J].
NUTT, JG ;
CARTER, JH ;
WOODWARD, WR .
NEUROLOGY, 1995, 45 (08) :1613-1616